How two of the most commonly prescribed opioid analgesics compare on pharmacology, potency, side effects, overdose risk, and the road to opioid use disorder.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.
Hydrocodone and oxycodone are both Schedule II opioid analgesics prescribed for moderate to severe pain. Oxycodone is roughly 1.5 times as potent as hydrocodone on a milligram for milligram basis, has a slightly faster onset, and is more commonly associated with euphoric drug abuse. Hydrocodone is the most prescribed opioid in the United States and is usually combined with acetaminophen, which adds a liver toxicity ceiling rather than reducing addiction risk. Both drugs bind to mu-opioid receptors in the central nervous system, both produce physical dependence within weeks of daily use, and both can cause fatal overdose through respiratory depression. The clinically meaningful difference is not which drug is safer but how each is prescribed, and how quickly an honest medical use can slide into compulsive opioid use.
What hydrocodone and oxycodone are
Hydrocodone and oxycodone are semi-synthetic opioid analgesics derived from thebaine, an alkaloid found in the opium poppy. Both are classified as Schedule II controlled substances under the Controlled Substances Act by the United States Drug Enforcement Administration, the second most restrictive category, reserved for medications with a recognised medical use and a high potential for abuse. They sit alongside fentanyl, morphine, methadone, and amphetamines in that classification. As prescription drugs used to treat moderate to severe pain, both are pain relievers, pain medications, and pain medicines that act in the central nervous system rather than at the site of injury.
Although the question of whether to take oxycodone or take hydrocodone is sometimes presented as a choice between two drugs, the similarities and differences between them are clinically narrow. Both are opioid drugs, both treat pain at the same receptor, both produce the same side effects, both produce physical dependence, and both can produce opioid use disorder. What is the difference between hydrocodone and oxycodone in practice is mostly a question of formulation, prescribing pattern, and the secondary ingredient in any given tablet.
Hydrocodone is the most prescribed opioid in the United States. It is almost always sold in combination with acetaminophen, also known as paracetamol outside North America, under brand names such as Vicodin, Norco, and Lortab. Pure hydrocodone is available as Hysingla ER and Zohydro ER, both extended-release formulations for chronic pain. The combination with acetaminophen is meant to provide additional analgesia, not to deter misuse; in practice the acetaminophen creates a ceiling on how much hydrocodone a person can swallow before risking acute liver failure.
Oxycodone is sold both as a single-active-ingredient product and in combination form. Brand names include OxyContin, the long-acting tablet that dominated chronic pain prescribing through the early 2000s; Roxicodone, the immediate-release tablet; Percocet, oxycodone combined with acetaminophen; and Endocet and Percodan, similar combination products. Oxycodone is also widely available as a generic, both alone and in combination, in tablet and oral solution form.
How both drugs work in the brain
Hydrocodone and oxycodone bind primarily to the opioid receptors in the brain, mainly the mu-opioid receptor, which is concentrated in the brainstem, the thalamus, the basal ganglia, the limbic system, and the spinal cord. When the receptor is activated, neurons in pain pathways are inhibited, the patient experiences pain relief, and downstream dopamine release in the ventral tegmental area produces a sense of warmth, calm, or feelings of euphoria. The same receptor activation in the brainstem slows breathing, which is why fatal opioid overdose is almost always a respiratory death rather than a cardiac one. Opioid pain relievers like hydrocodone and oxycodone work on these same opioid receptors throughout the brain and spinal cord.
Both are full agonists at the mu-opioid receptor, meaning they can fully activate it. This separates them from partial agonists such as buprenorphine, which has a ceiling effect on respiratory depression. There is no ceiling effect with hydrocodone or oxycodone. Doubling the dose roughly doubles the receptor activation, and at some dose, breathing stops. Tolerance to the analgesic and euphoric effects develops faster than tolerance to respiratory depression, which is one reason chronic users are at higher risk of fatal overdose when they relapse after a period of abstinence. Opioids like oxycodone and hydrocodone also slow how the brain and spinal cord perceive pain signals, which is why they can be effective when non-opioid medication has failed.
Oxycodone is also a weak agonist at the kappa-opioid receptor, which appears to contribute to its slightly different subjective profile compared with hydrocodone. Patients sometimes describe oxycodone as more euphoric and hydrocodone as more sedating, although individual variation is large and there is no clinically reliable way to predict which a given patient will prefer. In direct head-to-head studies, oxycodone is more likely than hydrocodone to produce that subjective euphoria, which is one reason oxycodone has historically been more sought after as a drug of misuse.
Potency, onset, and duration: differences between hydrocodone and oxycodone
On a milligram for milligram basis, oxycodone is stronger than hydrocodone, roughly 1.5 times as potent when both are taken orally. The difference in pain relief between equivalent doses of oxycodone and hydrocodone is real but modest: ten milligrams of oxycodone produces analgesia comparable to fifteen milligrams of hydrocodone in most patients. Compared with morphine taken orally, oxycodone is about 1.5 times as potent, and hydrocodone is approximately equipotent. Compared with intravenous fentanyl, both are dramatically less potent. None of this makes one safer than the other; it simply means that effective and lethal doses of oxycodone and hydrocodone are not interchangeable.
Immediate-release hydrocodone and oxycodone begin to work within 15 to 30 minutes and reach peak effect at 60 to 90 minutes. Their biological half-life is similar, around three to four and a half hours, which is why standard dosing for both is every 4 to 6 hours. Extended-release and modified-release formulations such as OxyContin and Hysingla ER are designed to release the drug over 12 or 24 hours, smoothing out the peaks and troughs. Patients sometimes crush extended-release tablets to defeat that mechanism, releasing the entire dose at once; current OxyContin tablets are formulated to resist this, but earlier generations were not, and counterfeit pills offer no resistance at all. Immediate-release and extended-release versions are not interchangeable: switching between them without dose adjustment is a recognised source of accidental overdose.
In short-term pain after surgery or injury, hydrocodone or oxycodone for the treatment of acute pain is generally prescribed at the lowest effective dose for the shortest reasonable period, typically three to seven days. For severe pain that has not responded to non-opioid medication including ibuprofen, paracetamol, or nonsteroidal anti-inflammatory drug therapy, an opioid drug may be added to a multimodal pain plan. The two drugs are similar enough in their analgesic effect that most clinical trials show no meaningful advantage of one over the other for typical post-operative pain management.
| Property | Hydrocodone | Oxycodone |
|---|---|---|
| Drug schedule | Schedule II (US DEA) | Schedule II (US DEA) |
| Receptor activity | Mu-opioid full agonist | Mu-opioid full agonist, weak kappa |
| Oral potency vs morphine | Approximately 1:1 | Approximately 1.5:1 |
| Hydrocodone : oxycodone equivalence | 1.5 mg : 1 mg | 1 mg : 1.5 mg hydrocodone |
| Onset (immediate release) | 15 to 30 minutes | 15 to 30 minutes |
| Peak effect | 60 to 90 minutes | 60 to 90 minutes |
| Half-life | 3.3 to 4.4 hours | 3 to 4.5 hours |
| Common brand names | Vicodin, Norco, Lortab, Hysingla ER, Zohydro ER | OxyContin, Roxicodone, Percocet, Percodan, Endocet |
| Usual combination | Acetaminophen (paracetamol) | Sometimes acetaminophen, often alone |
| Hepatic enzyme | CYP3A4, CYP2D6 | CYP3A4, CYP2D6 |
Comparison of oxycodone and hydrocodone: a clinical summary
What’s the difference between hydrocodone and oxycodone in clinical practice? A direct comparison of oxycodone and hydrocodone shows that the two drugs are similar in nearly every way: they share the same receptor target, the same metabolic enzymes, the same therapeutic window of 30 and 60 minutes for onset, and the same set of side effects. Oxycodone is often described as more potent than hydrocodone on a milligram basis, which is correct, but the difference is small enough that clinicians frequently interconvert dosing during transitions. The key differences are that oxycodone is more likely to be associated with euphoric drug abuse, while hydrocodone products dominate routine outpatient prescribing in the United States.
Studies suggest that oxycodone and hydrocodone work equally well to relieve moderate to severe pain when prescribed at equivalent doses. For short-term pain, both opioids are prescribed at the lowest effective dose for the shortest reasonable duration. To treat acute pain after surgery, either drug can be used; to treat severe pain that has failed first-line measures, oral oxycodone is sometimes preferred because of available higher unit doses, while hydrocodone is more commonly chosen for opioids prescribed in primary care because of physician familiarity. Both can be used to treat short-term pain in regulated practice and both can be used to treat moderate to severe pain when an opioid is clinically appropriate. The choice between hydrocodone or oxycodone addiction risk is much smaller than the choice between an opioid and a non-opioid plan.
Taking hydrocodone or taking oxycodone at the prescribed dose for a defined short period produces similar levels of pain relief. Both forms of oxycodone, immediate-release and extended-release, and both forms of hydrocodone, immediate-release combination and extended-release single-ingredient, share the same drug withdrawal profile. Hydrocodone can cause the same constellation of side effects as oxycodone; oxycodone can cause the same dependence as hydrocodone. The level of pain relief from a given dose, the level of overdose risk from a co-ingested sedative, and the level of misuse and addiction potential are broadly comparable. Hydrocodone and oxycodone are similar enough that the prescribing decision is rarely about which drug; it is about whether an opioid is the right tool at all.
In direct clinical comparisons such as oxycodone vs hydrocodone in acute extremity pain after emergency room presentation, the difference between the two is minimal at equivalent doses. Both deliver effective pain relief, both bind to mu opioid receptors in the central nervous system, both depress the central nervous system, and both are classified as Schedule II drugs in the United States and Schedule 8 medicines under the Therapeutic Goods Administration framework in Australia. Hydrocodone and oxycodone are classified alongside opioids like fentanyl and morphine, even though their misuse profile is somewhat lower than fentanyl. Oxycodone with acetaminophen, sold as Percocet, and hydrocodone with acetaminophen, sold as Vicodin or Norco, produce nearly identical pain medicine outcomes when matched for opioid equivalent dose. The patient with acute oxycodone use after recent surgery and the patient with acute hydrocodone use after the same surgery look similar in the recovery room; what diverges is what happens with the prescription bottle a month later. A higher incidence of constipation than with non-opioid analgesics is the most reliably reported difference between either opioid and ibuprofen or paracetamol. Drug abuse and addiction develop in the same way with either drug, and an honest opioid abuse pattern, whether of hydrocodone or oxycodone, shares the same trajectory.
Side effects and what to expect
The side effect profile of hydrocodone and oxycodone is nearly identical because both act on the same receptor in the same way. The most common short-term side effects are constipation, drowsiness, nausea, vomiting, dry mouth, dizziness, sedation, headache, sweating, and itching. Constipation is the only one that does not improve with tolerance. Patients on either drug for more than a few days routinely need a stimulant laxative such as senna and a stool softener; bulk-forming fibre alone is usually inadequate and can make the constipation worse. For mild to moderate pain, an anti-inflammatory medication such as ibuprofen, aspirin, or another nonsteroidal anti-inflammatory drug is often a safer first-line analgesic than either opioid.
Drowsiness and slowed reaction time are dose dependent and unpredictable. Patients should not drive, operate machinery, or make irreversible decisions for at least 48 hours after starting either drug, and should be cautious about combining it with anything else that depresses the central nervous system. Alcohol, benzodiazepines such as alprazolam and diazepam, gabapentinoids such as gabapentin and pregabalin, sleep aids such as zolpidem, and even some antihistamines all add to opioid sedation and respiratory depression risk.
Long-term use of either drug produces predictable problems: opioid-induced hyperalgesia, where the patient becomes more sensitive to pain rather than less; suppressed testosterone and other hormonal changes; reduced libido and fertility; chronic constipation that can become severe enough to cause bowel obstruction; sleep-disordered breathing; and dental decay, particularly with high-acid liquid formulations. Patients on chronic opioid therapy should expect their prescribing clinician to monitor liver function tests if they are on combination products with acetaminophen, because acetaminophen toxicity is the leading cause of acute liver failure in the United States and is dose-dependent.
Overdose, respiratory depression, and drug interactions
Fatal overdose on hydrocodone or oxycodone alone is uncommon at prescribed doses in opioid-tolerant patients, but it becomes common when the drug is combined with anything else that depresses breathing. The U.S. Centers for Disease Control and Prevention has documented that the great majority of prescription opioid overdose deaths involve at least one other central nervous system depressant. Benzodiazepines are the most frequent co-factor; alcohol is a close second. Patients should be told plainly that a glass of wine and a Norco at bedtime is not a small risk.
Both drugs are metabolised in the liver, primarily by the cytochrome P450 enzymes CYP3A4 and CYP2D6. CYP2D6 converts hydrocodone to hydromorphone and oxycodone to oxymorphone, both of which are more potent than the parent drug. Patients who are CYP2D6 ultra-rapid metabolisers, a genetic variant present in roughly 5 to 10 percent of people of European descent and up to 25 percent in some North African populations, produce more active metabolite from the same dose and can experience sedation, respiratory depression, and overdose at apparently normal doses. Poor metabolisers, by contrast, may report inadequate pain relief. CYP3A4 inhibitors such as clarithromycin, erythromycin, certain antifungals, ritonavir, and grapefruit juice can raise drug levels; strong inducers such as rifampin, carbamazepine, and St John’s wort can lower them.
Signs of opioid overdose, which apply equally to hydrocodone and oxycodone, are the classic opioid toxidrome: pinpoint pupils, slow shallow breathing or no breathing, profound sedation that does not respond to shouting or sternal rub, bluish lips or fingertips, and gurgling or snoring respiration. Naloxone, sold as Narcan and Kloxxado, reverses the respiratory depression by displacing the opioid from the receptor. Anyone with an opioid prescription, especially at higher doses or with co-prescribed sedatives, should keep naloxone in the home and ensure household members know how to use it.
Dependence, tolerance, and opioid use disorder
Two related but distinct things happen with regular use of hydrocodone or oxycodone. The first is physical dependence, also called substance dependence: the body adapts to daily opioid exposure, and stopping abruptly produces a recognisable opioid withdrawal syndrome with classic withdrawal symptoms. The second is opioid use disorder, defined behaviourally by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, as a pattern of compulsive use, loss of control, craving, and continued use despite harm. Almost everyone who takes either drug daily for more than two or three weeks becomes physically dependent. Only a subset develops opioid use disorder, and it is impossible to predict in advance who will. Major depressive disorder, anxiety, and other underlying mental health conditions raise that risk substantially.
Several patient-level risk factors raise the probability of progression to a substance use disorder. A personal or family history of drug abuse or alcohol use disorder is the strongest. Untreated depression, post-traumatic stress disorder, generalised anxiety, and attention deficit disorder all increase risk. Younger age at first use, history of childhood trauma, and a social environment in which opioid use is normalised also matter. Prescription duration matters too: research has consistently shown that the probability of long-term use rises sharply once an initial opioid prescription extends beyond about a week, and again beyond about a month.
Behavioural signs of an emerging problem look the same with hydrocodone and oxycodone. Running out of pills early. Asking for early refills. Doctor shopping or filling prescriptions at multiple pharmacies. Combining the prescription with alcohol or benzodiazepines to amplify the effect. Crushing tablets to release the dose faster. Buying opioids from non-medical sources. Lying to family or clinicians about how much is being taken. Continuing to take the medication after the original pain has resolved. Each of these signals can occur alone in someone who is not addicted, but combinations and patterns over weeks are the clinically meaningful red flags.
Opioid withdrawal: signs and symptoms
Acute opioid drug withdrawal from either drug is uncomfortable but not generally life-threatening in an otherwise healthy adult. The signs and symptoms of opioid drug withdrawal typically begin 6 to 12 hours after the last dose of a short-acting opioid such as immediate-release hydrocodone or oxycodone, peak around 36 to 72 hours, and resolve over 5 to 10 days. The classic features are muscle aches, joint pain, sweating, chills, gooseflesh, runny nose, watery eyes, abdominal cramping, diarrhoea, nausea, vomiting, yawning, restless legs, and pronounced insomnia. Cravings can be intense throughout, and disturbed sleep can produce daytime fatigue and shortness of breath on exertion.
Long-acting modified-release dosage formulations such as OxyContin and Hysingla ER produce a slightly delayed onset and a longer course of drug withdrawal. A subacute phase of disturbed sleep, low energy, anxiety, depressed mood, and intermittent cravings runs for several weeks beyond the acute phase. This is the period in which unsupervised attempts to stop most often fail, because the physical symptoms have eased but the patient is left flat, irritable, and exposed to the cues that originally triggered use. The dose of opioid at the time of discontinuation, the dose escalation history, and the length of daily use all shape how severe the withdrawal will be.
Medical detoxification under supervision is dramatically more tolerable than unsupervised withdrawal. Standard options include a planned taper of the original opioid; transition onto buprenorphine, often as Suboxone, with subsequent taper; or methadone-based detox in regulated settings. Adjunctive medications used during detox include clonidine or lofexidine for autonomic signs and symptoms, non-opioid analgesics for muscle and joint pain, anti-emetics, antidiarrhoeals, and short-term sleep support that avoids benzodiazepines. The most dangerous moment in any opioid taper is the relapse window after a period of reduced tolerance, when a return to the previous dose carries a high risk of fatal overdose. Patients with serotonin-affecting medications such as SSRIs in the picture also need their full medication list reviewed before any new opioid agonist therapy is started, because of the interaction risks between opioids and serotonergic drugs.
Treatment options for hydrocodone and oxycodone addiction
Addiction treatment for oxycodone or hydrocodone use disorder is built around three medication options, with a clear evidence base for each. Buprenorphine, often dispensed as Suboxone, is a partial mu-opioid agonist that occupies the same receptor as the original drug but with a respiratory depression ceiling that reduces overdose risk. Methadone, a long-acting full agonist, is dispensed in regulated opioid treatment programs and is well established as opioid agonist therapy for severe opioid use disorder. Naltrexone, particularly the long-acting injectable Vivitrol, blocks the mu-opioid receptor entirely and is used in patients who have completed detox and want to remain opioid-free.
Behavioural addiction treatment is layered on top of the pharmacology. Cognitive behavioural therapy, motivational interviewing, contingency management, and twelve-step facilitation all have evidence of effect in opioid use disorder. The combination of medication and structured therapy is the most reliable predictor of long-term recovery from oxycodone addiction or hydrocodone addiction. Treatment for the abuse and addiction associated with these drugs is also the moment to address the alcohol use, benzodiazepine use, or untreated mental health condition that often shares the room with the prescription.
Withdrawal symptoms drive many failed attempts to stop on the patient’s own. Medically supervised detox replaces those withdrawal symptoms with a planned taper, an alpha-2 agonist such as clonidine or lofexidine for autonomic features, anti-emetics, and sleep support that avoids benzodiazepines. Two drugs of misuse are addressed together where indicated, because abuse of opioids rarely travels alone. The goal of detox is not just to clear the opioid but to give the patient a foothold for the longer recovery work that follows.
Why the distinction matters less than people think
Patients and clinicians sometimes spend considerable energy on the question of whether hydrocodone or oxycodone is safer, less addictive, or more appropriate for a given pain syndrome. The honest clinical answer is that the differences between hydrocodone and oxycodone are smaller than the differences between any opioid and no opioid. Both sit at the centre of the modern opioid epidemic; both contributed to the rise in chronic noncancer pain prescribing through the 1990s and 2000s; both carry the same potential for addiction and abuse. The much more important questions are whether an opioid is the right tool for this specific pain, what the planned duration is, how the prescription will be tapered, what non-opioid pain management strategies are in place, and how the patient and their family will recognise the early signs of a problem.
For most acute pain after surgery or injury, the evidence does not strongly favour one over the other. For chronic pain, the recommendation has shifted decisively over the past decade against routine opioid use at all, with non-opioid medications such as gabapentin and pregabalin, duloxetine, topical agents, and structured physical therapy taking priority. The Centers for Disease Control and Prevention guidelines and the corresponding guidance from the United Kingdom’s National Institute for Health and Care Excellence both reflect this shift. The default question with hydrocodone or oxycodone for chronic pain is no longer which to choose, but whether to prescribe an opioid at all.
The alcohol picture sitting alongside opioid use
A common pattern in the patients who arrive at our centre is heavy alcohol use running quietly alongside an opioid prescription. The pain story is the one the patient brings up first; the drinking is mentioned only on the second or third interview, and often only after a partner mentions it. Alcohol and prescription opioids do the same thing to the central nervous system, and they do it through different but converging pathways. Combined, they produce deep sedation, profound respiratory depression, and the kind of overdose that kills people in bed rather than on the street.
Heavy drinking also damages the same metabolic and hormonal systems that opioids affect: it disrupts sleep architecture, lowers testosterone, raises cortisol, worsens mood, and accelerates opioid tolerance through shared CNS depressant tolerance pathways. Patients who think they are managing their pain with a few drinks at night are usually escalating both the alcohol and the opioid over time. Any honest assessment of someone on chronic hydrocodone or oxycodone has to ask explicitly about drinking, and the answer must be taken at face value rather than rounded down.
Treatment at Phuket Island Rehab
Patients arrive at Phuket Island Rehab for hydrocodone, oxycodone, or combination-product use disorder from several starting points. Some have been on a legitimate prescription for years and have moved into compulsive use without ever buying a pill on the street. Some started with a legitimate prescription and progressed to heroin or fentanyl when the prescription was cut. Some are using diverted oxycodone or counterfeit pills bought through informal channels and want to step out of that environment entirely. Each path requires a different opening week of treatment, and the first task is to read the patient honestly rather than fit them into a single protocol.
Our medical detox is supervised by an addiction medicine physician and nursing team experienced with prescription opioid withdrawal. The default approach for moderate to high dose use is induction onto buprenorphine, usually as Suboxone, followed by a planned taper over one to three weeks. For patients with lower dose use or those who want to remain entirely opioid-free, a non-opioid detox is possible using clonidine, lofexidine, and adjunctive medications, accepting that the first week is harder. Methadone-based detox is available where clinically indicated. The pace is set by symptoms, not by a calendar.
Therapy runs in parallel from day one. Detox is the medical task, recovery is the psychological one, and they cannot be sequenced. Patients work with our counsellors on the underlying pain story, on relapse prevention specific to the post-detox vulnerability window, on managing the alcohol use that almost always accompanies prescription opioid problems, on the family relationships that have been organised around dosing for years, and on building a life that does not require an opioid bedtime. Long-term outcomes are strongly tied to length of stay, with the literature consistently favouring residential programmes of 60 days or more for moderate to severe opioid use disorder.
When prescription opioid use has become more than occasional
Many of the people who reach out to our team are not in obvious crisis. They are still working, still seeing the same prescriber, still describing themselves as a pain patient rather than an opioid patient. What has shifted is that they no longer feel they are choosing the medication; the medication is choosing them. The bedtime dose creeps earlier in the evening. The bottle empties two or three days before the refill date. A bad week ends with a friend’s leftover pills. Drinking is heavier than it used to be, and morning anxiety is louder than it was a year ago.
If that pattern is familiar, the question is no longer whether the original pain justified the prescription. It is whether the current pattern is moving in the direction the patient wants their life to go. A conversation with an addiction medicine specialist, a properly supervised taper, and time away from the environment that has shaped the habit are reasonable next steps. They are not a failure of pain management. They are pain management catching up with where the prescription has actually gone.
Summary
Hydrocodone and oxycodone are both Schedule II opioid analgesics that bind to the mu-opioid receptor, produce comparable pain relief, share nearly identical side effect profiles, and carry similar overdose and addiction risks when taken outside the prescribed plan. Oxycodone is moderately more potent on a milligram basis, hydrocodone is more frequently prescribed in routine settings and almost always combined with acetaminophen. Neither is a safe long-term solution for chronic pain, and both produce dependence within weeks of daily use. Opioid use disorder is a behavioural diagnosis that can develop around either drug, and the alcohol use that often runs quietly alongside prescription opioid use is a major modifier of overdose risk.
As Dr. Ponlawat Pitsuwan puts it, “The patients I worry about most are not the ones who buy oxycodone on the street. They are the ones who have been on hydrocodone for a year, drink three nights a week, sleep poorly, and have not been asked an honest question about either by anyone in their life. The pill bottle in the kitchen cabinet does more damage than people credit it with, because no one is watching it.”
Frequently asked questions
Which is stronger, hydrocodone or oxycodone?
Oxycodone is roughly 1.5 times as potent as hydrocodone on a milligram for milligram basis when both are taken by mouth. Ten milligrams of oxycodone produces about the same level of analgesia and central nervous system effect as fifteen milligrams of hydrocodone. The difference is real but smaller than the difference between either drug and morphine, fentanyl, or buprenorphine, and is not clinically important when comparing equivalent doses. What matters more is the formulation, the prescribed schedule, and how long the prescription is intended to continue. Patients should never substitute one for the other on their own.
Which is more addictive, hydrocodone or oxycodone?
Both drugs activate the mu-opioid receptor in the same way and both produce physical dependence within two to three weeks of daily use. Survey data and prescription monitoring data suggest oxycodone is more often associated with euphoric drug abuse and recreational use, while hydrocodone is the more commonly prescribed and more commonly diverted opioid in the United States. The practical risk of opioid use disorder is similar for both drugs and depends much more on patient factors, prescription duration, dose, and co-use of alcohol or benzodiazepines than on which opioid is in the bottle. Calling one less addictive than the other gives patients false reassurance.
Can you mix hydrocodone and oxycodone?
Hydrocodone and oxycodone should not be taken together unless this combination has been explicitly planned and dose-adjusted by a prescribing clinician, which is rare. Both drugs act at the same receptor, and stacking them produces additive sedation, additive respiratory depression, and a higher risk of overdose without a meaningful additional benefit in pain relief. Patients who find themselves combining the two from different prescriptions, or who are tempted to take a friend’s oxycodone on top of their own hydrocodone, are signalling a problem that deserves a clinical conversation rather than a workaround.
How long does hydrocodone or oxycodone stay in your system?
Both immediate-release hydrocodone and immediate-release oxycodone have plasma half-lives of around three to four and a half hours, meaning a single dose is mostly cleared within about a day. Both are detectable in urine for two to four days after the last dose in most patients, longer in chronic high-dose users. Standard 5-panel drug tests will pick up both, although hydrocodone and oxycodone may require a more specific opiate or opioid expanded panel to be reliably distinguished from morphine and codeine. Extended-release formulations such as OxyContin produce slightly longer detection windows.
Can hydrocodone or oxycodone be safely tapered at home?
Stable, motivated patients with strong support and no significant co-use of alcohol, benzodiazepines, or other substances can sometimes successfully taper either drug at home under outpatient supervision. Residential treatment becomes the better option when previous outpatient attempts have stalled, when alcohol or other substance use is part of the picture, when underlying mental health conditions are unstable, when the home environment is where the original opioid use developed, or when the patient simply needs to be removed from the prescribing relationship to make a clean break. Tapering the dose under medical supervision, in whatever setting, is dramatically safer than stopping abruptly or attempting a cold-turkey detox alone.
What is the difference between Percocet, OxyContin, Vicodin, and Norco?
Percocet is oxycodone combined with acetaminophen, usually 5, 7.5, or 10 milligrams of oxycodone alongside 325 milligrams of acetaminophen. OxyContin is extended-release oxycodone alone, designed for chronic pain. Vicodin and Norco are both hydrocodone combined with acetaminophen, with Norco typically containing 325 milligrams of acetaminophen per tablet and the older Vicodin formulations using 500 or 750 milligrams; Norco formulations have largely replaced the older higher-acetaminophen Vicodin tablets because of liver toxicity concerns. All four are Schedule II controlled substances and all four can produce dependence and opioid use disorder.
Sources
U.S. Drug Enforcement Administration. Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling
U.S. Food and Drug Administration. Information about Medication-Assisted Treatment (MAT). https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat
Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
National Institute on Drug Abuse. Prescription Opioids DrugFacts. https://nida.nih.gov/publications/drugfacts/prescription-opioids
Substance Abuse and Mental Health Services Administration. Medications for Substance Use Disorders. https://www.samhsa.gov/medications-substance-use-disorders
National Institute for Health and Care Excellence (UK). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193). https://www.nice.org.uk/guidance/ng193
Therapeutic Goods Administration (Australia). Prescription opioids: information for consumers. https://www.tga.gov.au/safety/safety/safety-alerts/prescription-opioids-information-consumers
Hydrocodone | Oxycodone | Opioid analgesic | Schedule II controlled substance | Mu-opioid receptor | Acetaminophen (paracetamol) | Vicodin | Norco | Lortab | OxyContin | Roxicodone | Percocet | Endocet | Hysingla ER | Zohydro ER | Morphine | Hydromorphone | Oxymorphone | Fentanyl | Buprenorphine | Naloxone (Narcan) | Methadone | Heroin | Opioid use disorder | DSM-5 | Physical dependence | Opioid tolerance | Opioid withdrawal | Respiratory depression | CYP3A4 | CYP2D6 | Cytochrome P450 | Drug overdose | Chronic pain | Acute pain | Pain management | Prescription drug | Drug Enforcement Administration | Centers for Disease Control and Prevention | National Institute on Drug Abuse | Substance Abuse and Mental Health Services Administration | NICE (UK) | TGA (Australia) | Phuket Island Rehab